Sally Przybranowski

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index3.7kcitations49works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(21), Multiple Myeloma Research and Treatments(14), Ubiquitin and proteasome pathways(14), Melanoma and MAPK Pathways(9), Chronic Lymphocytic Leukemia Research(7)

Publications49 total

Supplementary Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Supplementary Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023Open Access
Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Methods from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Data from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Methods from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Tables from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Supporting Information: Figures from Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
2023Open Access
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Clinical Cancer Research·2022· 48 cited
Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression
Journal of Medicinal Chemistry·2020· 19 citedOpen Access
Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin–MLL Interaction with Strong <i>In Vivo</i> Antitumor Activity
Journal of Medicinal Chemistry·2020· 39 citedOpen Access
Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression
Journal of Medicinal Chemistry·2018· 291 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Donna McEachern(31), Shaomeng Wang(30), Jeanne A. Stuckey(25), Longchuan Bai(24), Chao‐Yie Yang(24), Ester Fernández‐Salas(16), Duxin Sun(15), Mi Wang(14), Jiantao Hu(12), Jennifer L. Meagher(11), Liu Liu(10), Jiao Ji(10), Hengbang Wang(10), Yifan Zhai(10), Dajun Yang(10), Wilbur R. Leopold(9), Yali Dou(9), Daniel F. Hayes(9), Shunqiang Li(9), Jing Deng(9)